November 11, 2022
Article
In an interview with Targeted Oncology, Ashley Ross, MD, PhD, discussed his recent advanced in prostate cancer, research around prostate cancer genomics, PET for staging and for identification of local disease, and more.
September 12, 2022
Article
The combination of enfortumab vedotin plus pembrolizumab led to a confirmed overall response rate of 64.5% in patients with metastatic urothelial cancer.
September 11, 2022
Article
Perioperative nivolumab in patients with RCC, at high risk for recurrence, did not see an improved RFS, but analyses within the phase 3 trial could inform future research.
June 07, 2022
Article
Reduced risk of metastatic progression and improved overall survival seen with darolutamide in patients with nonmetastatic castration-resistant prostate cancer.
February 20, 2022
Article
Updated findings from the phase 3 KEYNOTE-564 trial may further support adjuvant pembrolizumab as a new standard of care for patients with renal cell carcinoma with high risk of recurrence.